Author(s): Abhinav Raj Ghosh, K. L. Krishna, Seema Mehdi, Nandini HS, Chandan HM, Bhooshitha AN


DOI: 10.5958/0974-360X.2020.00619.8   

Address: Abhinav Raj Ghosh, K. L. Krishna*, Seema Mehdi, Nandini HS, Chandan HM, Bhooshitha AN
Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru-570015, Karnataka, India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 7,     Year - 2020

Cancer chemotherapy is a complicated targeting approach due to the ability of cancer cells to undergo metastasis and differentiation. Several biomarkers have been identified for cancer therapy, they are of three main types namely predictive, prognostic, and diagnostic each with its characteristic to determine the condition of the patient. However, the full potential of novel targets for cancer therapy has not been comprehended and many obstacles remain, from the validation of novel targets to the design of specific agents, till evaluation of these agents in both preclinical and clinical settings. In maximizing the benefits of molecular therapeutics of cancer, it is necessary to have an understanding of the underlying molecular abnormalities and mechanisms involved. This review encompasses the current treatment approaches for Breast, Lung, Colorectal and Hepatocellular Carcinoma and the possible role of novel biomarkers which have been identified in the last five years and their respective transduction pathways, in the context of their potential as targets for cancer therapy.

Cite this article:
Abhinav Raj Ghosh, K. L. Krishna, Seema Mehdi, Nandini HS, Chandan HM, Bhooshitha AN. Contemporaneous Novel Therapeutic Targets Recognized for their potential role in Colorectal, Lung, Breast, and Hepatocellular Carcinoma-A Review. Research J. Pharm. and Tech. 2020; 13(7): 3494-3500. doi: 10.5958/0974-360X.2020.00619.8

Abhinav Raj Ghosh, K. L. Krishna, Seema Mehdi, Nandini HS, Chandan HM, Bhooshitha AN. Contemporaneous Novel Therapeutic Targets Recognized for their potential role in Colorectal, Lung, Breast, and Hepatocellular Carcinoma-A Review. Research J. Pharm. and Tech. 2020; 13(7): 3494-3500. doi: 10.5958/0974-360X.2020.00619.8   Available on:

1. Cooper GM. The Development and Causes of Cancer. Cell Mol Approach 2nd Ed [Internet]. 2000 [cited 2019 Aug 23]; Available from:
2. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res. 2008 Jun;17(3):303–40.
3. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015 Jun;4(3):256–69.
4. Haggar FA, Boushey RP. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clin Colon Rectal Surg. 2009 Nov;22(4):191–7.
5. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2003 Jul 17;349(3):247–57.
6. Krämer I, Lipp H-P. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32(1):1–14.
7. Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal Cancer Immunotherapy. Discov Med. 2013 May;15(84):301–8.
8. Morita R, Hirohashi Y, Torigoe T, Ito-Inoda S, Takahashi A, Mariya T, et al. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy. Clin Cancer Res. 2016 Jul 1;22(13):3298–309.
9. Guéguinou M, Harnois T, Crottes D, Uguen A, Deliot N, Gambade A, et al. SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline. Oncotarget. 2016 Apr 18;7(24):36168–84.
10. Rupp C, Scherzer M, Rudisch A, Unger C, Haslinger C, Schweifer N, et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction. Oncogene. 2015 Feb;34(7):815–25.
11. Yun Q, Wong CC, Yu J. IDDF2019-ABS-0203 SCNN1B Functions as a tumor suppressor in colorectal cancer by inhibiting RAS-RAF-MEK-ERK pathway. Gut. 2019 Jun 1;68(Suppl 1):A20–A20.
12. Wan L, Yu W, Shen E, Sun W, Liu Y, Kong J, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 2019 Jan 1;68(1):118–29.
13. Wang H-Y, Long Q-Y, Tang S-B, Xiao Q, Gao C, Zhao Q-Y, et al. Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer. Nucleic Acids Res. 2019 Mar 18;47(5):2349–64.
14. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
15. Kanwal M, Ding X-J, Cao Y. Familial risk for lung cancer. Oncol Lett. 2017 Feb;13(2):535–42.
16. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013 Nov;22(6):540.
17. Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K. RET fusion gene: Translation to personalized lung cancer therapy [Internet]. Cancer Science. 2013 [cited 2019 Aug 5]. Available from:
18. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016 Mar 1;17(3):299–308.
19. Muralidharan R, Panneerselvam J, Chen A, Zhao YD, Munshi A, Ramesh R. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015 Dec;22(12):581–90.
20. La‐Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy [Internet]. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015 [cited 2019 Aug 5]. Available from: doi/abs/10.1002/phar.1643
21. Caiola E, Falcetta F, Giordano S, Marabese M, Garassino MC, Broggini M, et al. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. J Exp Clin Cancer Res. 2018 Dec 4;37(1):302.
22. Sironi J, Aranda E, Nordstrøm LU, Schwartz EL. Lysosome Membrane Permeabilization and Disruption of the Molecular Target of Rapamycin (mTOR)-Lysosome Interaction Are Associated with the Inhibition of Lung Cancer Cell Proliferation by a Chloroquinoline Analog. Mol Pharmacol. 2019 Jan 1;95(1):127–38.
23. Otsuki Y, Saya H, Arima Y. Prospects for new lung cancer treatments that target EMT signaling. Dev Dyn. 2018;247(3):462–72.
24. U.S. Breast Cancer Statistics [Internet]. 2019 [cited 2019 Aug 6]. Available from: symptoms/understand_bc/statistics
25. Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Przegla̜d Menopauzalny Menopause Rev. 2015 Sep;14(3):196–202.
26. Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) | Cancer Research [Internet]. [cited 2019 Aug 8]. Available from: 75/15_Supplement/2859.short#
27. JCI - TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer [Internet]. [cited 2019 Aug 8]. Available from:
28. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer | Cancer Immunology Research [Internet]. [cited 2019 Aug 8]. Available from: https:// cancerimmunolres.
29. Elbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser MW, et al. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Oncotarget. 2016 May 27;9(71):33459–70.
30. Geffken K, Spiegel S. Sphingosine kinase 1 in breast cancer. Adv Biol Regul. 2018 Jan 1; 67:59–65.
31. Lee M-H, Koh D, Na H, Ka N-L, Kim S, Kim H-J, et al. MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells. Autophagy. 2018 May 4;14(5):812–24.
32. Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018 Feb 28; 12:26–32.
33. Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015 Dec 15;3(4):732–6.
34. Hien DT, Takai A, Forgues M, Wang XW. Abstract 1985: Oncogenic activation of RNA binding proteins and c-Myc signaling in hepatocellular carcinoma. Cancer Res. 2016 Jul 15;76(14 Supplement):1985–1985.
35. Lin Y-Y, Tan C-T, Chen C-W, Ou D-L, Cheng A-L, Hsu C. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Semin Liver Dis. 2018 Nov;38(4):379–88.
36. Dietrich P, Gaza A, Wormser L, Fritz V, Hellerbrand C, Bosserhoff AK. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma. Neoplasia. 2019 Mar 1;21(3):257–68.
37. Zahid KR, Han S, Zhou F, Raza U. Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death. Cell Oncol. 2019 Feb 1;42(1):55–66.
38.   Tsuge S, Saberi B, Cheng Y, Wang Z, Kim A, Luu H, et al. Detection of Novel Fusion Transcript VTI1A-CFAP46 in Hepatocellular Carcinoma. Gastrointest Tumors. 2019;6(1–2):11–27.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available